Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

NCT00447681
View directory record Official record
Conditions
Healthy
Interventions
ILV-094
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 15, 2026, 8:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

NCT01495065
View directory record Official record
Conditions
Community-acquired Infection
Interventions
GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

NCT01101646
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
rabeprazole sodium
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-7500 in Healthy Adults

NCT06011317
View directory record Official record
Conditions
Healthy Subjects
Interventions
EDG-7500, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

NCT00925574
View directory record Official record
Conditions
Psoriasis
Interventions
CNTO 1959; Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of NPT200-11 in Healthy Subjects

NCT02606682
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NPT200-11, Placebo
Drug
Lead sponsor
Neuropore Therapies Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3337641 in Japanese and Caucasian Healthy Participants

NCT03083561
View directory record Official record
Conditions
Healthy
Interventions
LY3337641, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

NCT01508988
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-9054
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

NCT07540494
View directory record Official record
Conditions
Healthy Adult
Interventions
5 Methoxy N,N Dimethyltryptamine, GH001 Aerosol Delivery System
Drug · Device
Lead sponsor
GH Research Ireland Limited
Industry
Eligibility
21 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TB006, Sterile saline (Placebo)
Drug · Other
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

NCT01453907
View directory record Official record
Conditions
Anthrax
Interventions
ETI-204, "Anthim", placebo
Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

NCT01741493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-494, Placebo, Tofacitinib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481
View directory record Official record
Conditions
Normal Renal Function, Impaired Renal Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

NCT03301298
View directory record Official record
Conditions
Healthy
Interventions
SXC-2023, Placebo oral capsule
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

NCT02433093
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Volunteer
Interventions
Basimglurant, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

NCT00404274
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Warfarin oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

NCT04480697
View directory record Official record
Conditions
Healthy
Interventions
HPG1860
Drug
Lead sponsor
Hepagene (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort

NCT01294540
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Drug: E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

NCT03341884
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Ipatasertib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Miami, Florida • Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 15, 2026, 8:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers

NCT07843693
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Upadacitinib, Tofacitinib, Baricitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

NCT00785915
View directory record Official record
Conditions
Healthy
Interventions
AZD6765, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 15, 2026, 8:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

NCT07736638
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-859, Placebo for ABBV-859
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 15, 2026, 8:37 PM EDT